ATL 1102

ATL 1102 (Avicursen) is a novel second-generation antisense oligonucleotide to CD49d mRNA

Product Specifications

CAS Number

[350263-41-1]

Product Name Alternative

ISIS-107248; Avicursen

UNSPSC

12352208

Target

Integrin

Type

Oligonucleotides

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/atl-1102.html

Solubility

10 mM in H2O

Smiles

[ATL1102]

Molecular Formula

C233H327N60O129P19S19

Molecular Weight

7230.14

References & Citations

[1]Duchartre Y, Bachl S, Kim HN, et al. Effects of CD49d-targeted antisense-oligonucleotide on α4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies. PLoS One. 2017;12 (11) :e0187684. |[2]Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G; ATL1102 Study Group. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS [published correction appears in Neurology. 2015 Jan 6;84 (1) :105]. Neurology. 2014;83 (20) :1780-1788.